Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts
•In 2020, COVID-19 dislodged TB as the top infectious disease cause of mortality globally.•Globally, an estimated 10.0 million people developed active TB disease in 2019, with 1.4 million TB deaths.•The WHO regions of South-East Asia, Africa, and the Western Pacific had the most cases of TB.•Progres...
Uloženo v:
| Vydáno v: | International journal of infectious diseases Ročník 113; číslo Suppl 1; s. S7 - S12 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Canada
Elsevier Ltd
01.12.2021
Elsevier |
| Témata: | |
| ISSN: | 1201-9712, 1878-3511, 1878-3511 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | •In 2020, COVID-19 dislodged TB as the top infectious disease cause of mortality globally.•Globally, an estimated 10.0 million people developed active TB disease in 2019, with 1.4 million TB deaths.•The WHO regions of South-East Asia, Africa, and the Western Pacific had the most cases of TB.•Progress in achieving the United Nations (UN) General Assembly End TB targets remains slow.•TB services need to be ramped up, and underlying drivers of TB need be addressed.
The October 2020 Global TB report reviews TB control strategies and United Nations (UN) targets set in the political declaration at the September 2018 UN General Assembly high-level meeting on TB held in New York. Progress in TB care and prevention has been very slow. In 2019, TB remained the most common cause of death from a single infectious pathogen. Globally, an estimated 10.0 million people developed TB disease in 2019, and there were an estimated 1.2 million TB deaths among HIV-negative people and an additional 208, 000 deaths among people living with HIV. Adults accounted for 88% and children for 12% of people with TB. The WHO regions of South-East Asia (44%), Africa (25%), and the Western Pacific (18%) had the most people with TB. Eight countries accounted for two thirds of the global total: India (26%), Indonesia (8.5%), China (8.4%), the Philippines (6.0%), Pakistan (5.7%), Nigeria (4.4%), Bangladesh (3.6%) and South Africa (3.6%). Only 30% of the 3.5 million five-year target for children treated for TB was met. Major advances have been development of new all oral regimens for MDRTB and new regimens for preventive therapy. In 2020, the COVID-19 pandemic dislodged TB from the top infectious disease cause of mortality globally. Notably, global TB control efforts were not on track even before the advent of the COVID-19 pandemic. Many challenges remain to improve sub-optimal TB treatment and prevention services. Tuberculosis screening and diagnostic test services need to be ramped up. The major drivers of TB remain undernutrition, poverty, diabetes, tobacco smoking, and household air pollution and these need be addressed to achieve the WHO 2035 TB care and prevention targets. National programs need to include interventions for post-tuberculosis holistic wellbeing. From first detection of COVID-19 global coordination and political will with huge financial investments have led to the development of effective vaccines against SARS-CoV2 infection. The world now needs to similarly focus on development of new vaccines for TB utilizing new technological methods. |
|---|---|
| AbstractList | The October 2020 Global TB report reviews TB control strategies and United Nations (UN) targets set in the political declaration at the September 2018 UN General Assembly high-level meeting on TB held in New York. Progress in TB care and prevention has been very slow. In 2019, TB remained the most common cause of death from a single infectious pathogen. Globally, an estimated 10.0 million people developed TB disease in 2019, and there were an estimated 1.2 million TB deaths among HIV-negative people and an additional 208, 000 deaths among people living with HIV. Adults accounted for 88% and children for 12% of people with TB. The WHO regions of South-East Asia (44%), Africa (25%), and the Western Pacific (18%) had the most people with TB. Eight countries accounted for two thirds of the global total: India (26%), Indonesia (8.5%), China (8.4%), the Philippines (6.0%), Pakistan (5.7%), Nigeria (4.4%), Bangladesh (3.6%) and South Africa (3.6%). Only 30% of the 3.5 million five-year target for children treated for TB was met. Major advances have been development of new all oral regimens for MDRTB and new regimens for preventive therapy. In 2020, the COVID-19 pandemic dislodged TB from the top infectious disease cause of mortality globally. Notably, global TB control efforts were not on track even before the advent of the COVID-19 pandemic. Many challenges remain to improve sub-optimal TB treatment and prevention services. Tuberculosis screening and diagnostic test services need to be ramped up. The major drivers of TB remain undernutrition, poverty, diabetes, tobacco smoking, and household air pollution and these need be addressed to achieve the WHO 2035 TB care and prevention targets. National programs need to include interventions for post-tuberculosis holistic wellbeing. From first detection of COVID-19 global coordination and political will with huge financial investments have led to the development of effective vaccines against SARS-CoV2 infection. The world now needs to similarly focus on development of new vaccines for TB utilizing new technological methods. •In 2020, COVID-19 dislodged TB as the top infectious disease cause of mortality globally.•Globally, an estimated 10.0 million people developed active TB disease in 2019, with 1.4 million TB deaths.•The WHO regions of South-East Asia, Africa, and the Western Pacific had the most cases of TB.•Progress in achieving the United Nations (UN) General Assembly End TB targets remains slow.•TB services need to be ramped up, and underlying drivers of TB need be addressed. The October 2020 Global TB report reviews TB control strategies and United Nations (UN) targets set in the political declaration at the September 2018 UN General Assembly high-level meeting on TB held in New York. Progress in TB care and prevention has been very slow. In 2019, TB remained the most common cause of death from a single infectious pathogen. Globally, an estimated 10.0 million people developed TB disease in 2019, and there were an estimated 1.2 million TB deaths among HIV-negative people and an additional 208, 000 deaths among people living with HIV. Adults accounted for 88% and children for 12% of people with TB. The WHO regions of South-East Asia (44%), Africa (25%), and the Western Pacific (18%) had the most people with TB. Eight countries accounted for two thirds of the global total: India (26%), Indonesia (8.5%), China (8.4%), the Philippines (6.0%), Pakistan (5.7%), Nigeria (4.4%), Bangladesh (3.6%) and South Africa (3.6%). Only 30% of the 3.5 million five-year target for children treated for TB was met. Major advances have been development of new all oral regimens for MDRTB and new regimens for preventive therapy. In 2020, the COVID-19 pandemic dislodged TB from the top infectious disease cause of mortality globally. Notably, global TB control efforts were not on track even before the advent of the COVID-19 pandemic. Many challenges remain to improve sub-optimal TB treatment and prevention services. Tuberculosis screening and diagnostic test services need to be ramped up. The major drivers of TB remain undernutrition, poverty, diabetes, tobacco smoking, and household air pollution and these need be addressed to achieve the WHO 2035 TB care and prevention targets. National programs need to include interventions for post-tuberculosis holistic wellbeing. From first detection of COVID-19 global coordination and political will with huge financial investments have led to the development of effective vaccines against SARS-CoV2 infection. The world now needs to similarly focus on development of new vaccines for TB utilizing new technological methods. The October 2020 Global TB report reviews TB control strategies and United Nations (UN) targets set in the political declaration at the September 2018 UN General Assembly high-level meeting on TB held in New York. Progress in TB care and prevention has been very slow. In 2019, TB remained the most common cause of death from a single infectious pathogen. Globally, an estimated 10.0 million people developed TB disease in 2019, and there were an estimated 1.2 million TB deaths among HIV-negative people and an additional 208, 000 deaths among people living with HIV. Adults accounted for 88% and children for 12% of people with TB. The WHO regions of South-East Asia (44%), Africa (25%), and the Western Pacific (18%) had the most people with TB. Eight countries accounted for two thirds of the global total: India (26%), Indonesia (8.5%), China (8.4%), the Philippines (6.0%), Pakistan (5.7%), Nigeria (4.4%), Bangladesh (3.6%) and South Africa (3.6%). Only 30% of the 3.5 million five-year target for children treated for TB was met. Major advances have been development of new all oral regimens for MDRTB and new regimens for preventive therapy. In 2020, the COVID-19 pandemic dislodged TB from the top infectious disease cause of mortality globally. Notably, global TB control efforts were not on track even before the advent of the COVID-19 pandemic. Many challenges remain to improve sub-optimal TB treatment and prevention services. Tuberculosis screening and diagnostic test services need to be ramped up. The major drivers of TB remain undernutrition, poverty, diabetes, tobacco smoking, and household air pollution and these need be addressed to achieve the WHO 2035 TB care and prevention targets. National programs need to include interventions for post-tuberculosis holistic wellbeing. From first detection of COVID-19 global coordination and political will with huge financial investments have led to the development of effective vaccines against SARS-CoV2 infection. The world now needs to similarly focus on development of new vaccines for TB utilizing new technological methods.The October 2020 Global TB report reviews TB control strategies and United Nations (UN) targets set in the political declaration at the September 2018 UN General Assembly high-level meeting on TB held in New York. Progress in TB care and prevention has been very slow. In 2019, TB remained the most common cause of death from a single infectious pathogen. Globally, an estimated 10.0 million people developed TB disease in 2019, and there were an estimated 1.2 million TB deaths among HIV-negative people and an additional 208, 000 deaths among people living with HIV. Adults accounted for 88% and children for 12% of people with TB. The WHO regions of South-East Asia (44%), Africa (25%), and the Western Pacific (18%) had the most people with TB. Eight countries accounted for two thirds of the global total: India (26%), Indonesia (8.5%), China (8.4%), the Philippines (6.0%), Pakistan (5.7%), Nigeria (4.4%), Bangladesh (3.6%) and South Africa (3.6%). Only 30% of the 3.5 million five-year target for children treated for TB was met. Major advances have been development of new all oral regimens for MDRTB and new regimens for preventive therapy. In 2020, the COVID-19 pandemic dislodged TB from the top infectious disease cause of mortality globally. Notably, global TB control efforts were not on track even before the advent of the COVID-19 pandemic. Many challenges remain to improve sub-optimal TB treatment and prevention services. Tuberculosis screening and diagnostic test services need to be ramped up. The major drivers of TB remain undernutrition, poverty, diabetes, tobacco smoking, and household air pollution and these need be addressed to achieve the WHO 2035 TB care and prevention targets. National programs need to include interventions for post-tuberculosis holistic wellbeing. From first detection of COVID-19 global coordination and political will with huge financial investments have led to the development of effective vaccines against SARS-CoV2 infection. The world now needs to similarly focus on development of new vaccines for TB utilizing new technological methods. |
| Author | Abubakar, Ibrahim Katoto, Patrick D.M.C. Bulabula, André N.H. McHugh, Timothy D. Chakaya, Jeremiah Kapata, Nathan Hasnain, Seyed Ehtesham Zumla, Alimuddin Ntoumi, Francine Sam-Agudu, Nadia A. Nachega, Jean B. Aklillu, Eleni Tiberi, Simon Khan, Mishal Mfinanga, Sayoki Mwaba, Peter Fatima, Razia |
| AuthorAffiliation | t Dept of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA b Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom h Lusaka Apex Medical University, Lusaka, Zambia n Department of Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa k Muhimbili University of Health and Allied Sciences, Dar-Es-Salaam, Tanzania g Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital-Huddinge, SE-141 86 Stockholm, Sweden s Department of Medicine, Stellenbosch University, Cape Town, South Africa i Zambia National Public Health Institute, Ministry of Health, Lusaka, Zambia v Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom w Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK f Institute for Tr |
| AuthorAffiliation_xml | – name: e Université Marien Gouabi, Fondation Congolaise pour la Recherche Médicale, Brazzaville, Congo – name: p International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria – name: t Dept of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA – name: u Department of Epidemiology, Infectious Diseases and Microbiology, Center for Global Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA – name: k Muhimbili University of Health and Allied Sciences, Dar-Es-Salaam, Tanzania – name: d National TB Control Program, Common Unit (HIV,TB,Malaria), Chak Shahzad, Islamabad, Pakistan – name: w Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK – name: x Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom – name: r Department of Pediatrics and Child Health, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana – name: g Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital-Huddinge, SE-141 86 Stockholm, Sweden – name: a Department of Medicine, Therapeutics and Dermatology, Kenyatta University, Nairobi, Kenya – name: y Institute of Global health, University College London, London, United Kingdom – name: m Department of Bichemical Engineering and Biotechnology, Indian Institute of Technology, New Delhi, India – name: c London School of Hygiene and Tropical Medicine, London, UK – name: f Institute for Tropical Diseases, University of Tübingen, Germany – name: b Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom – name: l Nelson Mandela African Institution of Science and Technology, Arusha, Tanzania – name: o Department of Global Health, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa – name: i Zambia National Public Health Institute, Ministry of Health, Lusaka, Zambia – name: n Department of Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa – name: z Department of Infection, Division of Infection and Immunity, University College London, and NIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, United Kingdom – name: j National Institute for Medical Research, Dar-Es-Salaam, Tanzania – name: v Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom – name: q Institute of Human Virology and Department of Pediatrics, University of Maryland School of Medicine, Baltimore, USA – name: s Department of Medicine, Stellenbosch University, Cape Town, South Africa – name: h Lusaka Apex Medical University, Lusaka, Zambia |
| Author_xml | – sequence: 1 givenname: Jeremiah surname: Chakaya fullname: Chakaya, Jeremiah email: chakaya.jm@gmail.com organization: Department of Medicine, Therapeutics and Dermatology, Kenyatta University, Nairobi, Kenya – sequence: 2 givenname: Mishal surname: Khan fullname: Khan, Mishal email: Mishal.Khan@lshtm.ac.uk organization: London School of Hygiene and Tropical Medicine, London, UK – sequence: 3 givenname: Francine surname: Ntoumi fullname: Ntoumi, Francine email: fntoumi@fcrm-congo.com organization: Université Marien Gouabi, Fondation Congolaise pour la Recherche Médicale, Brazzaville, Congo – sequence: 4 givenname: Eleni surname: Aklillu fullname: Aklillu, Eleni email: Eleni.Aklillu@ki.se organization: Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital-Huddinge, SE-141 86 Stockholm, Sweden – sequence: 5 givenname: Razia surname: Fatima fullname: Fatima, Razia email: drraziafatima@gmail.com organization: National TB Control Program, Common Unit (HIV,TB,Malaria), Chak Shahzad, Islamabad, Pakistan – sequence: 6 givenname: Peter surname: Mwaba fullname: Mwaba, Peter email: pbmwaba2000@gmail.com organization: Lusaka Apex Medical University, Lusaka, Zambia – sequence: 7 givenname: Nathan surname: Kapata fullname: Kapata, Nathan email: nkapata@gmail.com organization: Zambia National Public Health Institute, Ministry of Health, Lusaka, Zambia – sequence: 8 givenname: Sayoki surname: Mfinanga fullname: Mfinanga, Sayoki email: gsmfinanga@yahoo.com organization: National Institute for Medical Research, Dar-Es-Salaam, Tanzania – sequence: 9 givenname: Seyed Ehtesham surname: Hasnain fullname: Hasnain, Seyed Ehtesham email: seyedhasnain@gmail.com organization: Department of Bichemical Engineering and Biotechnology, Indian Institute of Technology, New Delhi, India – sequence: 10 givenname: Patrick D.M.C. surname: Katoto fullname: Katoto, Patrick D.M.C. email: katotopatrick@gmail.com organization: Department of Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa – sequence: 11 givenname: André N.H. surname: Bulabula fullname: Bulabula, André N.H. email: andybulabula@gmail.com organization: Department of Global Health, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa – sequence: 12 givenname: Nadia A. surname: Sam-Agudu fullname: Sam-Agudu, Nadia A. email: nsamagudu@ihvnigeria.org organization: International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria – sequence: 13 givenname: Jean B. surname: Nachega fullname: Nachega, Jean B. email: JBN16@pitt.edu organization: Department of Medicine, Stellenbosch University, Cape Town, South Africa – sequence: 14 givenname: Simon surname: Tiberi fullname: Tiberi, Simon email: simon.tiberi@nhs.net organization: Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom – sequence: 15 givenname: Timothy D. surname: McHugh fullname: McHugh, Timothy D. email: t.mchugh@ucl.ac.uk organization: Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom – sequence: 16 givenname: Ibrahim surname: Abubakar fullname: Abubakar, Ibrahim email: i.abubakar@ucl.ac.uk organization: Institute of Global health, University College London, London, United Kingdom – sequence: 17 givenname: Alimuddin surname: Zumla fullname: Zumla, Alimuddin email: a.zumla@ucl.ac.uk organization: Department of Infection, Division of Infection and Immunity, University College London, and NIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, United Kingdom |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33716195$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:148554665$$DView record from Swedish Publication Index (Karolinska Institutet) |
| BookMark | eNqFksluFDEQhlsoiCzwAhyQjxzowVsvg1AkiCBEioSEwtnyUk488diD3T0oN96BN-RJcDMziMkhnFz-q76_LFcdVwchBqiq5wTPCCbt68XMLZyZUUzJDNOidY-qI9J3fc0aQg5KTDGp5x2hh9VxzguMMW_b_kl1yFhHWjJvjip37qOSHl2NCpIefcwuoy-wimlAxRijXz9-lrv1oAcXQ0YxoOEG0A57j9SYDIRXaEgghyWEAclg0CrBusQFQWBtcctPq8dW-gzPtudJ9fXjh6uzT_Xl5_OLs3eXtW4JHmoLsulxoxSbUwJgpSQSE82NoYQpAGDMWGPmDeVGy46YVmlaRE4NNppxdlJdbHxNlAuxSm4p052I0ok_QkzXQqbBaQ9CWtawThuDcc_V3Ki26RvN2w6ssoAnr3rjlb_DalR7blvptkQgeMsKWupPN_UlswSjyw8k6few_UxwN-I6rkXPGaNNVwxebg1S_DZCHsTSZQ3eywBxzII2mPCe9nzq9eLfXn-b7GZbCvpNgU4x5wRWaDfIaSSltfOCYDGtkViIaY3EtEYC06JNz6D30J37g9DbDQRlumsHSWTtIGgwLpXtKd_vHsbf3MO1d8Fp6W_h7n_wbwDc98k |
| CitedBy_id | crossref_primary_10_1016_j_cellimm_2024_104865 crossref_primary_10_1016_j_ijtb_2022_04_002 crossref_primary_10_1136_bmjopen_2022_067613 crossref_primary_10_1016_j_ijtb_2022_04_007 crossref_primary_10_3389_fpubh_2024_1362465 crossref_primary_10_1038_s41598_022_16437_3 crossref_primary_10_1371_journal_pone_0281591 crossref_primary_10_1016_j_jvscit_2025_101788 crossref_primary_10_1039_D4RA02746A crossref_primary_10_1039_D2BM01835G crossref_primary_10_1007_s00586_024_08453_w crossref_primary_10_3390_ijerph20054556 crossref_primary_10_1016_j_resinv_2024_01_010 crossref_primary_10_1155_2022_7340330 crossref_primary_10_2147_IJN_S326480 crossref_primary_10_1111_jgh_16124 crossref_primary_10_3389_fmolb_2023_1348337 crossref_primary_10_3390_ijerph20032640 crossref_primary_10_1099_jmm_0_001814 crossref_primary_10_1155_2022_5071816 crossref_primary_10_1063_5_0257908 crossref_primary_10_1080_03067319_2022_2147427 crossref_primary_10_7705_biomedica_7500 crossref_primary_10_1080_17435889_2025_2478806 crossref_primary_10_1371_journal_pone_0312072 crossref_primary_10_1186_s13690_025_01641_0 crossref_primary_10_3390_idr13030074 crossref_primary_10_1016_j_heliyon_2024_e31185 crossref_primary_10_7759_cureus_16236 crossref_primary_10_3389_fphar_2022_932686 crossref_primary_10_3389_fcimb_2023_1215294 crossref_primary_10_1016_j_jiph_2024_02_012 crossref_primary_10_3389_fimmu_2023_1093640 crossref_primary_10_1038_s41598_024_53880_w crossref_primary_10_2174_0115672018295247240426055330 crossref_primary_10_1038_s41598_024_65682_1 crossref_primary_10_1016_j_ijid_2022_09_030 crossref_primary_10_7759_cureus_80900 crossref_primary_10_1080_02286203_2024_2371684 crossref_primary_10_2147_IDR_S377182 crossref_primary_10_1155_jotm_6631193 crossref_primary_10_1007_s12291_022_01044_w crossref_primary_10_3889_oamjms_2022_8817 crossref_primary_10_12998_wjcc_v11_i14_3167 crossref_primary_10_3389_fcimb_2022_792617 crossref_primary_10_4103_ijcm_ijcm_795_23 crossref_primary_10_7759_cureus_64586 crossref_primary_10_1186_s40249_024_01270_9 crossref_primary_10_1002_cbdv_202500474 crossref_primary_10_1016_j_tetlet_2024_155383 crossref_primary_10_1016_j_csbj_2022_09_031 crossref_primary_10_34067_KID_0000000000000551 crossref_primary_10_4103_ijmy_ijmy_229_24 crossref_primary_10_3389_fpubh_2022_848370 crossref_primary_10_1016_j_compmedimag_2023_102186 crossref_primary_10_13005_bbra_2923 crossref_primary_10_1186_s44263_025_00175_5 crossref_primary_10_2147_IDR_S449684 crossref_primary_10_1242_dmm_049018 crossref_primary_10_15252_embr_202052252 crossref_primary_10_2147_NDT_S347579 crossref_primary_10_1097_FTD_0000000000001170 crossref_primary_10_1128_msystems_00562_24 crossref_primary_10_3390_molecules30102251 crossref_primary_10_1177_03000605231189134 crossref_primary_10_1002_sim_9974 crossref_primary_10_1080_23744235_2024_2309348 crossref_primary_10_3389_fcimb_2024_1455819 crossref_primary_10_1186_s12879_023_07996_5 crossref_primary_10_1080_22221751_2024_2322663 crossref_primary_10_2196_66029 crossref_primary_10_1111_crj_70071 crossref_primary_10_3923_asb_2025_119_127 crossref_primary_10_52711_2231_5659_2023_00057 crossref_primary_10_2147_TACG_S457395 crossref_primary_10_1186_s12879_022_07946_7 crossref_primary_10_1186_s12879_022_07694_8 crossref_primary_10_1007_s11686_023_00729_3 crossref_primary_10_1016_j_socscimed_2024_116639 crossref_primary_10_3390_tropicalmed7080194 crossref_primary_10_1016_j_jctube_2025_100559 crossref_primary_10_3390_ijerph22071154 crossref_primary_10_1186_s12879_022_07792_7 crossref_primary_10_1186_s40001_021_00611_w crossref_primary_10_1007_s00261_023_03997_9 crossref_primary_10_1007_s42399_023_01568_z crossref_primary_10_1016_j_bbrc_2021_09_008 crossref_primary_10_3390_microorganisms11071697 crossref_primary_10_3762_bjnano_15_42 crossref_primary_10_1007_s11831_022_09818_4 crossref_primary_10_1016_j_ijtb_2023_05_009 crossref_primary_10_1016_j_micres_2023_127319 crossref_primary_10_3389_fpsyt_2025_1497074 crossref_primary_10_1080_07391102_2022_2039298 crossref_primary_10_3389_fcimb_2024_1453466 crossref_primary_10_3390_antibiotics11081038 crossref_primary_10_1016_j_jveb_2023_01_002 crossref_primary_10_1016_j_envres_2022_114100 crossref_primary_10_1155_2023_2502314 crossref_primary_10_22207_JPAM_17_4_56 crossref_primary_10_1016_j_intimp_2024_112799 crossref_primary_10_1186_s12913_024_11959_0 crossref_primary_10_1016_j_radcr_2022_10_032 crossref_primary_10_3390_ijerph182211984 crossref_primary_10_1186_s41983_023_00642_6 crossref_primary_10_12998_wjcc_v10_i10_3284 crossref_primary_10_3389_fpubh_2021_757133 crossref_primary_10_1016_j_bioorg_2024_107511 crossref_primary_10_3389_fsurg_2022_815514 crossref_primary_10_1111_imj_16032 crossref_primary_10_1016_j_jddst_2023_105039 crossref_primary_10_3390_idr15020017 crossref_primary_10_3390_biology11050755 crossref_primary_10_3390_ijerph19031574 crossref_primary_10_3390_pharmaceutics13091479 crossref_primary_10_1080_08927022_2021_1968390 crossref_primary_10_3390_molecules27165335 crossref_primary_10_3390_biomimetics7030088 crossref_primary_10_1038_s41598_024_71720_9 crossref_primary_10_1155_2023_6226200 crossref_primary_10_1186_s12879_023_08533_0 crossref_primary_10_1080_09273948_2024_2437124 crossref_primary_10_1186_s13065_024_01182_7 crossref_primary_10_3390_diagnostics11122221 crossref_primary_10_1007_s11306_023_02052_4 crossref_primary_10_1038_s42003_024_06785_3 crossref_primary_10_1371_journal_pone_0277192 crossref_primary_10_2147_IDR_S515231 crossref_primary_10_4081_hls_2025_13505 crossref_primary_10_1186_s12906_025_05002_w crossref_primary_10_3389_fimmu_2024_1438989 crossref_primary_10_4103_ijpvm_ijpvm_346_23 crossref_primary_10_7554_eLife_73055 crossref_primary_10_3390_ijms26031155 crossref_primary_10_1038_s41421_024_00653_4 crossref_primary_10_2147_IDR_S404804 crossref_primary_10_1186_s41256_024_00392_9 crossref_primary_10_1016_j_tibs_2023_12_008 crossref_primary_10_1016_j_diagmicrobio_2023_115959 crossref_primary_10_1093_rheumatology_keae185 crossref_primary_10_2147_ITT_S455744 crossref_primary_10_1056_NEJMoa2212537 crossref_primary_10_1080_1040841X_2024_2321494 crossref_primary_10_1155_2023_6726654 crossref_primary_10_1186_s42269_022_00969_9 crossref_primary_10_1093_ced_llae549 crossref_primary_10_1002_iub_2578 crossref_primary_10_2147_JMDH_S401660 crossref_primary_10_7759_cureus_56092 crossref_primary_10_1080_00207233_2025_2462440 crossref_primary_10_1016_j_nbd_2024_106721 crossref_primary_10_3389_fmicb_2024_1372647 crossref_primary_10_52692_1857_0011_2024_2_79_51 crossref_primary_10_1073_pnas_2318003121 crossref_primary_10_4103_njcp_njcp_734_22 crossref_primary_10_1186_s12891_022_05600_6 crossref_primary_10_1021_jacs_2c08238 crossref_primary_10_1186_s12890_021_01678_1 crossref_primary_10_1155_2022_7003809 crossref_primary_10_1002_prot_26504 crossref_primary_10_1016_j_ajg_2024_01_013 crossref_primary_10_3389_fimmu_2021_750496 crossref_primary_10_1002_hsr2_1789 crossref_primary_10_1208_s12249_023_02510_1 crossref_primary_10_3889_oamjms_2021_6517 crossref_primary_10_12771_emj_2025_00059 crossref_primary_10_3389_fpubh_2023_1128525 crossref_primary_10_1186_s12889_023_16180_y crossref_primary_10_3390_ph18010070 crossref_primary_10_3390_bios13060589 crossref_primary_10_2147_IDR_S441536 crossref_primary_10_1016_j_heliyon_2022_e12001 crossref_primary_10_3389_fpubh_2023_1216924 crossref_primary_10_3390_tropicalmed10070176 crossref_primary_10_1007_s42452_025_06995_2 crossref_primary_10_3389_fphar_2023_1248331 crossref_primary_10_1016_j_diagmicrobio_2023_115921 crossref_primary_10_1089_sur_2022_042 crossref_primary_10_1016_j_radcr_2022_02_085 crossref_primary_10_1089_sur_2023_089 crossref_primary_10_1016_j_jctube_2025_100534 crossref_primary_10_1186_s12889_023_17495_6 crossref_primary_10_3389_fphar_2023_1263726 crossref_primary_10_1016_j_meegid_2024_105703 crossref_primary_10_7189_jogh_14_04023 crossref_primary_10_1177_11786361221099878 crossref_primary_10_1172_JCI161944 crossref_primary_10_1016_j_radcr_2022_02_077 crossref_primary_10_1016_j_ijid_2021_03_046 crossref_primary_10_1016_j_jorep_2023_100196 crossref_primary_10_4103_indianjotol_indianjotol_131_22 crossref_primary_10_1186_s13073_022_01020_2 crossref_primary_10_1093_femsle_fnac106 crossref_primary_10_1186_s12940_023_01044_0 crossref_primary_10_3390_epidemiologia4020021 crossref_primary_10_1016_j_bbrc_2025_151575 crossref_primary_10_1016_j_tube_2023_102430 crossref_primary_10_7759_cureus_27746 crossref_primary_10_1186_s40249_024_01188_2 crossref_primary_10_3389_fimmu_2023_1305325 crossref_primary_10_1016_j_tube_2023_102424 crossref_primary_10_1002_ajoc_202400165 crossref_primary_10_1002_hpm_3489 crossref_primary_10_1007_s10389_023_02002_3 crossref_primary_10_1016_j_envpol_2022_120718 crossref_primary_10_3390_jcm12144843 crossref_primary_10_1016_j_jcot_2025_102973 crossref_primary_10_1038_s41598_023_36420_w crossref_primary_10_3389_fpsyt_2021_697508 crossref_primary_10_1038_s42003_023_04658_9 crossref_primary_10_3389_fcimb_2023_1292864 crossref_primary_10_1016_j_jconrel_2022_07_040 crossref_primary_10_1016_j_heliyon_2025_e42781 crossref_primary_10_1016_j_bios_2023_115514 crossref_primary_10_1111_eci_13913 crossref_primary_10_1186_s12891_022_05132_z crossref_primary_10_1016_j_sjbs_2021_06_029 crossref_primary_10_1177_20503121241241970 crossref_primary_10_3390_ijms25116245 crossref_primary_10_1007_s00894_022_05148_1 crossref_primary_10_1016_S2468_2667_21_00203_6 crossref_primary_10_1038_s41577_023_00941_2 crossref_primary_10_1016_j_ejmech_2024_116479 crossref_primary_10_1109_ACCESS_2024_3386208 crossref_primary_10_3390_technologies11010005 crossref_primary_10_1016_j_ijbiomac_2022_11_235 crossref_primary_10_1128_spectrum_04597_22 crossref_primary_10_1007_s13538_025_01751_8 crossref_primary_10_1128_spectrum_01262_21 crossref_primary_10_3389_fmed_2023_1136094 crossref_primary_10_1080_07391102_2023_2294496 crossref_primary_10_3389_fpubh_2023_1177618 crossref_primary_10_1183_16000617_0264_2021 crossref_primary_10_1016_j_ijmm_2022_151558 crossref_primary_10_1155_2022_7526501 crossref_primary_10_1186_s13568_022_01425_7 crossref_primary_10_3889_oamjms_2021_6558 crossref_primary_10_1051_e3sconf_202338802008 crossref_primary_10_1016_j_jped_2023_02_002 crossref_primary_10_1111_tmi_14066 crossref_primary_10_1016_j_compbiomed_2022_105453 crossref_primary_10_1093_aje_kwac186 crossref_primary_10_3389_fneur_2022_830969 crossref_primary_10_3389_fepid_2025_1405845 crossref_primary_10_1007_s00044_023_03039_5 crossref_primary_10_7759_cureus_67062 crossref_primary_10_3389_fmed_2022_798465 crossref_primary_10_2147_IDR_S466738 crossref_primary_10_1186_s12879_024_09771_6 crossref_primary_10_1016_j_molstruc_2022_133888 crossref_primary_10_3390_cells11030361 crossref_primary_10_1016_j_tube_2023_102340 crossref_primary_10_1186_s12889_024_19705_1 crossref_primary_10_3390_pharmaceutics15051521 crossref_primary_10_1186_s12887_024_05344_3 crossref_primary_10_1007_s11033_021_07095_1 crossref_primary_10_1093_ofid_ofac516 crossref_primary_10_1016_j_cegh_2024_101554 crossref_primary_10_1038_s41598_024_62386_4 crossref_primary_10_1186_s12879_025_10878_7 crossref_primary_10_1186_s12887_025_05704_7 crossref_primary_10_1186_s12879_024_10419_8 crossref_primary_10_3389_fmicb_2022_842017 crossref_primary_10_1186_s12889_023_16840_z crossref_primary_10_1097_MD_0000000000033372 crossref_primary_10_1515_cclm_2023_0293 crossref_primary_10_1016_j_clnesp_2025_05_028 crossref_primary_10_1080_20469047_2023_2246006 crossref_primary_10_1080_22221751_2023_2294858 crossref_primary_10_1186_s12879_025_11093_0 crossref_primary_10_1515_znc_2022_0092 crossref_primary_10_1590_1516_3180_2023_0279_r1_13052024 crossref_primary_10_1097_MD_0000000000037617 crossref_primary_10_1007_s00590_022_03376_y crossref_primary_10_1080_01969722_2022_2162736 crossref_primary_10_1002_bit_28929 crossref_primary_10_1111_jpc_15681 crossref_primary_10_1186_s40545_023_00634_0 crossref_primary_10_1128_jb_00314_24 crossref_primary_10_1038_s41598_025_89483_2 crossref_primary_10_1093_cid_ciac455 crossref_primary_10_1111_jpc_16073 crossref_primary_10_1080_10406638_2024_2444338 crossref_primary_10_26442_20751753_2024_3_202743 crossref_primary_10_3389_fimmu_2021_696491 crossref_primary_10_1080_10409238_2024_2411264 crossref_primary_10_1038_s41467_023_39300_z crossref_primary_10_1002_jcla_24256 crossref_primary_10_1007_s00203_025_04415_y crossref_primary_10_7717_peerj_cs_2246 crossref_primary_10_1038_s41598_024_56711_0 crossref_primary_10_1080_07391102_2023_2270528 crossref_primary_10_1128_spectrum_02477_21 crossref_primary_10_3390_ijms26062378 crossref_primary_10_1016_j_micpath_2022_105880 crossref_primary_10_1016_j_coph_2022_102283 crossref_primary_10_3390_ph15050536 crossref_primary_10_1016_S2352_3018_22_00301_0 crossref_primary_10_1080_14786419_2022_2124512 crossref_primary_10_25259_IJMR_368_23 crossref_primary_10_1016_j_chest_2021_10_014 crossref_primary_10_5812_jjm_134575 crossref_primary_10_1186_s12879_023_08460_0 crossref_primary_10_1265_ehpm_24_00381 crossref_primary_10_1016_j_meegid_2022_105325 crossref_primary_10_2217_pgs_2021_0096 crossref_primary_10_3390_molecules26206162 crossref_primary_10_3389_fcimb_2025_1579827 crossref_primary_10_3389_fcimb_2022_937811 crossref_primary_10_2147_NDT_S391751 crossref_primary_10_2147_DMSO_S523027 crossref_primary_10_3389_fgene_2022_899124 crossref_primary_10_1016_j_molstruc_2023_137255 crossref_primary_10_4103_ijnmr_ijnmr_316_21 crossref_primary_10_4103_ijpvm_ijpvm_69_24 crossref_primary_10_1183_23120541_00461_2022 crossref_primary_10_1016_j_ijbiomac_2023_125455 crossref_primary_10_2217_fmb_2023_0056 crossref_primary_10_2147_IDR_S351541 crossref_primary_10_1016_j_mayocp_2022_05_013 crossref_primary_10_4103_ijmy_ijmy_235_22 crossref_primary_10_1186_s12879_025_11068_1 crossref_primary_10_22207_JPAM_18_4_38 crossref_primary_10_3390_tropicalmed7090250 crossref_primary_10_1016_j_smim_2022_101672 crossref_primary_10_1177_20503121231187743 crossref_primary_10_1515_biol_2025_1081 crossref_primary_10_1080_17513758_2024_2394665 crossref_primary_10_3390_idr16050080 crossref_primary_10_1109_JSEN_2024_3523750 crossref_primary_10_3390_healthcare10020386 crossref_primary_10_1002_jbt_70119 crossref_primary_10_3390_ijerph19148227 crossref_primary_10_1002_hsr2_70792 crossref_primary_10_1088_1361_6528_adb7ea crossref_primary_10_3390_genes13101733 crossref_primary_10_3390_nano14191553 crossref_primary_10_3889_oamjms_2023_11292 crossref_primary_10_7759_cureus_55190 crossref_primary_10_1016_j_intimp_2025_114531 crossref_primary_10_3390_vaccines11071264 crossref_primary_10_1111_1756_185X_14328 crossref_primary_10_1155_2022_2742164 crossref_primary_10_1007_s00508_022_02009_y crossref_primary_10_1039_D2SC06858C crossref_primary_10_1186_s12905_024_03207_8 crossref_primary_10_1016_j_ijbiomac_2024_132332 crossref_primary_10_3390_ph16040581 crossref_primary_10_1016_j_ijid_2022_06_001 crossref_primary_10_3390_diagnostics14131456 crossref_primary_10_3389_frhs_2024_1273739 crossref_primary_10_4103_ijmy_ijmy_224_23 crossref_primary_10_3389_fmicb_2025_1582163 crossref_primary_10_3390_pharmaceutics16121584 crossref_primary_10_3390_fractalfract7040300 crossref_primary_10_2147_ITT_S436765 crossref_primary_10_1051_bioconf_20235708002 crossref_primary_10_3389_fpubh_2025_1550199 crossref_primary_10_1038_s41598_023_38707_4 crossref_primary_10_1016_j_ijid_2023_08_001 crossref_primary_10_1186_s12879_023_08268_y crossref_primary_10_1186_s12889_024_18794_2 crossref_primary_10_1016_j_ijtb_2025_05_003 crossref_primary_10_1016_j_molstruc_2025_142267 crossref_primary_10_1111_jgh_15878 crossref_primary_10_1016_j_trac_2024_117979 crossref_primary_10_4274_jcp_2022_71542 crossref_primary_10_1016_j_snb_2022_131968 crossref_primary_10_20473_fmi_v60i2_49749 crossref_primary_10_1007_s00586_023_07728_y crossref_primary_10_1016_j_micpath_2025_107861 crossref_primary_10_3389_fcimb_2022_959911 crossref_primary_10_12998_wjcc_v11_i28_6698 crossref_primary_10_1177_03000605231195156 crossref_primary_10_1016_j_ijtb_2023_01_004 crossref_primary_10_4103_NJM_NJM_41_23 crossref_primary_10_1016_j_bios_2022_114654 crossref_primary_10_1590_s2175_97902025e24388 crossref_primary_10_1002_eji_202149624 crossref_primary_10_4236_jbm_2025_137010 crossref_primary_10_1016_j_prrv_2024_08_002 crossref_primary_10_1371_journal_pntd_0011464 crossref_primary_10_1051_e3sconf_202338101101 crossref_primary_10_3390_s23156781 crossref_primary_10_1038_s41598_022_20017_w crossref_primary_10_3390_jcm11237009 crossref_primary_10_1093_bioadv_vbad090 crossref_primary_10_3390_diseases11020056 crossref_primary_10_1038_s41597_025_04838_8 crossref_primary_10_1002_ardp_202200172 crossref_primary_10_1177_11795484221142468 crossref_primary_10_1155_2023_6465182 crossref_primary_10_1080_10790268_2024_2426315 crossref_primary_10_1016_j_ijmm_2021_151544 crossref_primary_10_1016_j_micpath_2022_105826 crossref_primary_10_3389_ijph_2025_1607892 crossref_primary_10_20307_nps_2025_31_2_111 crossref_primary_10_3389_fpubh_2025_1577211 crossref_primary_10_3389_fcimb_2023_1280223 crossref_primary_10_1007_s00484_023_02524_1 crossref_primary_10_1186_s12879_025_10911_9 crossref_primary_10_1093_pubmed_fdac141 crossref_primary_10_1089_dna_2022_0282 crossref_primary_10_4081_aamr_2022_138 crossref_primary_10_1016_j_jep_2022_115249 crossref_primary_10_2196_43753 crossref_primary_10_1007_s11030_022_10453_1 crossref_primary_10_1186_s43168_023_00214_5 crossref_primary_10_3389_fmed_2023_1278716 crossref_primary_10_1093_omcr_omad023 crossref_primary_10_59556_japi_72_0637 crossref_primary_10_3389_fpubh_2025_1578658 crossref_primary_10_1134_S1070363224080139 crossref_primary_10_1093_inthealth_ihae059 crossref_primary_10_1097_MD_0000000000036371 crossref_primary_10_1590_0102_311xpt291321 crossref_primary_10_1186_s13063_023_07559_8 crossref_primary_10_1186_s12879_024_10378_0 crossref_primary_10_3389_fmicb_2023_1202752 crossref_primary_10_4103_ijmy_ijmy_89_24 crossref_primary_10_1088_1555_6611_acbf3b crossref_primary_10_1038_s41598_025_96260_8 crossref_primary_10_1002_adbi_202400174 crossref_primary_10_1186_s12879_025_11063_6 crossref_primary_10_1515_dx_2022_0044 crossref_primary_10_3389_fsurg_2022_815303 crossref_primary_10_1016_j_ijid_2023_10_015 crossref_primary_10_2147_RMHP_S386012 crossref_primary_10_1016_j_micpath_2021_105083 crossref_primary_10_1136_bcr_2021_245612 crossref_primary_10_1186_s13018_023_04059_y crossref_primary_10_1097_MD_0000000000039052 crossref_primary_10_1186_s12890_024_02893_2 crossref_primary_10_2147_IJGM_S502996 crossref_primary_10_1016_j_clinimag_2023_110024 crossref_primary_10_1016_j_ijtb_2025_08_013 crossref_primary_10_1051_e3sconf_202560904008 crossref_primary_10_1155_cjid_5549653 crossref_primary_10_3390_pathogens14060559 crossref_primary_10_1016_j_bioorg_2022_105807 crossref_primary_10_1128_spectrum_05162_22 crossref_primary_10_3389_fimmu_2022_882651 crossref_primary_10_7180_kmj_25_105 crossref_primary_10_1186_s12982_025_00684_6 crossref_primary_10_12688_f1000research_159002_2 crossref_primary_10_1002_pro_4644 crossref_primary_10_1016_j_jmgm_2025_109025 crossref_primary_10_1080_15257770_2023_2272641 crossref_primary_10_1186_s12931_022_02051_4 crossref_primary_10_3389_fcimb_2023_1255905 crossref_primary_10_1007_s00284_022_02949_8 crossref_primary_10_1029_2023GH000972 crossref_primary_10_1186_s12879_021_06807_z crossref_primary_10_12688_f1000research_159002_1 crossref_primary_10_3389_fmicb_2024_1344857 crossref_primary_10_3389_fsurg_2023_1236611 crossref_primary_10_2147_IMCRJ_S389204 crossref_primary_10_3389_fonc_2025_1529049 crossref_primary_10_1016_j_jpba_2022_115172 crossref_primary_10_1007_s42764_021_00057_8 crossref_primary_10_2147_IDR_S428652 crossref_primary_10_1155_2023_7829286 crossref_primary_10_1186_s13690_023_01160_w crossref_primary_10_1016_j_ijtb_2022_09_003 crossref_primary_10_1080_14656566_2022_2161881 crossref_primary_10_1186_s12879_024_10206_5 crossref_primary_10_1093_heapro_daad150 crossref_primary_10_1016_j_jiph_2022_08_016 crossref_primary_10_1016_j_molstruc_2022_134099 crossref_primary_10_3389_fped_2023_1188704 crossref_primary_10_1080_07391102_2024_2434026 crossref_primary_10_1039_D2RA04121A crossref_primary_10_5662_wjm_v12_i4_258 crossref_primary_10_7759_cureus_88118 crossref_primary_10_1038_s41598_022_20872_7 crossref_primary_10_1080_14756366_2023_2250575 crossref_primary_10_2106_JBJS_CC_22_00124 crossref_primary_10_5582_bst_2023_01325 crossref_primary_10_1038_s41589_022_01102_7 crossref_primary_10_1038_s41598_023_43310_8 crossref_primary_10_1080_02648725_2022_2076031 crossref_primary_10_1080_07853890_2023_2249004 crossref_primary_10_1186_s12889_021_12233_2 crossref_primary_10_1007_s00261_023_03869_2 crossref_primary_10_3390_nursrep12040084 crossref_primary_10_1016_j_ejmech_2022_114201 crossref_primary_10_3390_biomedicines9060692 crossref_primary_10_4103_ijmy_ijmy_18_24 crossref_primary_10_1080_07391102_2023_2227709 crossref_primary_10_1016_j_heliyon_2024_e30720 crossref_primary_10_1186_s12879_023_08112_3 crossref_primary_10_1002_ccr3_8224 crossref_primary_10_52547_ibj_26_3_240 crossref_primary_10_61708_vhezh846 crossref_primary_10_3390_biomedicines12071472 crossref_primary_10_1080_21645515_2022_2080443 crossref_primary_10_25881_20728255_2025_20_3_137 crossref_primary_10_1016_j_ejmech_2022_114698 crossref_primary_10_1016_j_jcot_2022_101852 crossref_primary_10_1007_s11760_023_02732_7 crossref_primary_10_1136_thoraxjnl_2021_218345 crossref_primary_10_11648_j_ajns_20251404_12 crossref_primary_10_4102_phcfm_v15i1_3764 crossref_primary_10_1186_s42269_023_01001_4 crossref_primary_10_1007_s15010_022_01916_6 crossref_primary_10_2147_IDR_S396022 crossref_primary_10_3389_fmed_2024_1502969 crossref_primary_10_3389_fcimb_2022_788692 crossref_primary_10_3390_ijms23105713 crossref_primary_10_2147_IDR_S413495 crossref_primary_10_2196_49123 crossref_primary_10_1186_s13019_025_03544_1 crossref_primary_10_1186_s12913_023_09783_z crossref_primary_10_5005_jp_journals_10081_1367 crossref_primary_10_1002_mgg3_2386 crossref_primary_10_1099_mic_0_001288 crossref_primary_10_3389_fmed_2023_1205446 crossref_primary_10_3389_fpubh_2022_994745 crossref_primary_10_7759_cureus_64138 crossref_primary_10_1016_j_idnow_2022_02_011 crossref_primary_10_1016_j_ijtb_2023_03_023 crossref_primary_10_1016_j_molstruc_2025_142560 crossref_primary_10_2147_RMHP_S494335 crossref_primary_10_1007_s10930_023_10135_3 crossref_primary_10_1038_s41598_022_21244_x crossref_primary_10_20473_ijph_v19i1_2024_15_27 crossref_primary_10_1016_j_cegh_2025_102123 crossref_primary_10_1177_2333794X241304375 crossref_primary_10_1016_j_bbagen_2022_130218 crossref_primary_10_3389_fcvm_2023_1076118 crossref_primary_10_1002_jcla_24478 crossref_primary_10_3389_fmolb_2022_906387 crossref_primary_10_1183_23120541_00113_2022 crossref_primary_10_1007_s11030_024_10985_8 crossref_primary_10_1111_exd_70134 crossref_primary_10_3390_molecules26227022 crossref_primary_10_3389_fmed_2021_812857 crossref_primary_10_1084_jem_20221334 crossref_primary_10_1016_j_heliyon_2023_e21956 crossref_primary_10_1016_j_sbsr_2025_100814 crossref_primary_10_3389_fphar_2022_1037814 crossref_primary_10_3389_fped_2022_966237 crossref_primary_10_1186_s12889_023_16934_8 crossref_primary_10_4081_monaldi_2025_3418 crossref_primary_10_1016_j_ijid_2021_09_048 crossref_primary_10_1097_MD_0000000000038034 crossref_primary_10_3389_fneur_2022_830029 crossref_primary_10_1007_s13312_022_2574_6 crossref_primary_10_1186_s12964_024_01713_8 crossref_primary_10_1007_s00018_024_05200_8 crossref_primary_10_1016_j_jbc_2023_105439 crossref_primary_10_3389_fimmu_2021_706081 crossref_primary_10_35817_publicuho_v8i3_814 |
| Cites_doi | 10.1038/s41598-019-47645-z 10.1093/cid/ciy1105 10.5588/ijtld.15.0873 10.1016/S1473-3099(19)30564-X 10.1038/s41418-020-00720-9 10.1056/NEJMoa1902129 10.1016/S2214-109X(20)30343-0 10.5588/ijtld.17.0498 10.1016/S1473-3099(09)70282-8 10.1016/S1473-3099(19)30309-3 10.1056/NEJMoa1313865 10.5588/ijtld.17.0706 10.1183/13993003.01596-2017 10.1016/S0140-6736(19)30024-8 10.1371/journal.pmed.1002595 10.1016/S2214-109X(18)30487-X 10.1093/ije/dyy144 10.1371/journal.pmed.1002152 10.5588/ijtld.20.0387 10.1056/NEJMoa1811867 10.1056/NEJMoa1112433 10.5588/ijtld.20.0067 10.5588/ijtld.19.0139 10.1056/NEJMoa1104875 10.1016/S0140-6736(10)61425-0 10.1093/cid/ciu572 10.1016/j.jctube.2016.03.001 10.1056/NEJMoa1806808 10.1002/14651858.CD003343.pub3 10.1371/journal.pmed.1002754 |
| ContentType | Journal Article |
| Copyright | 2021 The Author(s) Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
| Copyright_xml | – notice: 2021 The Author(s) – notice: Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ADTPV AOWAS D8T ZZAVC DOA |
| DOI | 10.1016/j.ijid.2021.02.107 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Freely available online SwePub Articles full text DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1878-3511 |
| EndPage | S12 |
| ExternalDocumentID | oai_doaj_org_article_af3537cdd0084b9db6585c467efbfe04 oai_swepub_ki_se_463585 PMC8433257 33716195 10_1016_j_ijid_2021_02_107 S1201971221001934 |
| Genre | Journal Article |
| GeographicLocations | Nigeria |
| GeographicLocations_xml | – name: Nigeria |
| GrantInformation_xml | – fundername: FIC NIH HHS grantid: D43 TW010937 – fundername: FIC NIH HHS grantid: R25 TW011217 – fundername: FIC NIH HHS grantid: R21 TW011706 – fundername: NICHD NIH HHS grantid: R01 HD089866 |
| GroupedDBID | --- --K .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 29J 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 7X7 88E 8C1 8FI 8FJ 8FQ 8R4 8R5 AAEDW AAFWJ AAIKJ AALRI AAQFI AAQXK AARKO AAXUO AAYWO ABBQC ABFRF ABMAC ABUWG ABWVN ACGFO ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEFWE AEKER AENEX AEUPX AEVXI AEXQZ AFJKZ AFKRA AFPKN AFPUW AFRHN AFTJW AGEKW AGHFR AGQPQ AGYEJ AHMBA AIGII AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP ASPBG AVWKF AZFZN BAWUL BCNDV BENPR BPHCQ BR6 BVXVI CCPQU CS3 DIK DU5 DWQXO E3Z EBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FNPLU FYUFA G-Q GBLVA GROUPED_DOAJ GX1 HMCUK HVGLF HZ~ IHE IXB J1W KQ8 M1P M3C M3G M41 MO0 N9A O-L O9- OD- OK1 OO. OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO Q2X Q38 QTD R2- ROL RPZ RWL RXW SDF SDG SEL SES SEW SSZ TAE UKHRP UNMZH Z5R ~HD 0SF 3V. 6I. AACTN AAFTH ABVKL AFCTW NCXOZ RIG 9DU AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 7X8 5PM ADTPV AOWAS D8T ZZAVC |
| ID | FETCH-LOGICAL-c610t-fea5805bb3921eefaa1a01c4dd213beee33dfdd9524dca71d6bc2e3342d0dc343 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 683 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000735777000002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1201-9712 1878-3511 |
| IngestDate | Fri Oct 03 12:49:23 EDT 2025 Tue Nov 25 03:37:24 EST 2025 Tue Sep 30 16:49:14 EDT 2025 Sat Sep 27 21:34:01 EDT 2025 Mon Jul 21 05:58:07 EDT 2025 Sat Nov 29 07:01:42 EST 2025 Tue Nov 18 22:34:21 EST 2025 Fri Feb 23 02:43:42 EST 2024 Tue Oct 14 19:34:31 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | Suppl 1 |
| Keywords | Prevention Global TB Report 2020 Tuberculosis Treatment |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c610t-fea5805bb3921eefaa1a01c4dd213beee33dfdd9524dca71d6bc2e3342d0dc343 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doaj.org/article/af3537cdd0084b9db6585c467efbfe04 |
| PMID | 33716195 |
| PQID | 2501482845 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_af3537cdd0084b9db6585c467efbfe04 swepub_primary_oai_swepub_ki_se_463585 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8433257 proquest_miscellaneous_2501482845 pubmed_primary_33716195 crossref_citationtrail_10_1016_j_ijid_2021_02_107 crossref_primary_10_1016_j_ijid_2021_02_107 elsevier_sciencedirect_doi_10_1016_j_ijid_2021_02_107 elsevier_clinicalkey_doi_10_1016_j_ijid_2021_02_107 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-12-01 |
| PublicationDateYYYYMMDD | 2021-12-01 |
| PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Canada |
| PublicationPlace_xml | – name: Canada |
| PublicationTitle | International journal of infectious diseases |
| PublicationTitleAlternate | Int J Infect Dis |
| PublicationYear | 2021 |
| Publisher | Elsevier Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
| References | Swindells, Ramchandani, Gupta, Benson, Leon-Cruz, Mwelase (bib0150) 2019; 380 Houben, Dodd (bib0085) 2016; 13 Cegielski, Dalton, Yagui, Wattanaamornkiet, Volchenkov, Via (bib0035) 2014; 59 Corbett, Bandason, Duong, Dauya, Makamure, Churchyard (bib0045) 2010; 376 Nunn, Phillips, Meredith, Chiang, Conradie, Dalai (bib0115) 2019; 380 Dooley, Chaisson (bib0060) 2009; 9 WHO (bib0175) 2019 African Union (bib0005) 2007 Allwood, van der Zalm, Makanda, Mortimer, Andre, Uzochukwu (bib0015) 2019; 9 Bulabula, Nelson, Musafiri, Machekano, Sam-Agudu, Diacon (bib0030) 2019; 69 Noubiap, Nansseu, Nyaga, Nkeck, Endomba, Kaze (bib0110) 2019; 7 Lee, Bing, Kiang, Bashir, Spath, Stelzle (bib0095) 2020; 8 Sterling, Villarino, Borisov, Shang, Gordin, Bliven-Sizemore (bib0135) 2011; 365 Subbaraman, Nathavitharana, Mayer, Satyanarayana, Chadha, Arinaminpathy (bib0140) 2019; 16 Gler, Skripconoka, Sanchez-Garavito, Xiao, Cabrera-Rivero, Vargas-Vasquez (bib0075) 2012; 366 Trébucq, Schwoebel (bib0155) 2016; 20 Trebucq, Schwoebel, Kashongwe, Bakayoko, Kuaban, Noeske (bib0160) 2018; 22 Bisimwa, Nachega, Warren, Theron, Metcalfe, Shah (bib0025) 2020; 26 Alipanah, Jarlsberg, Miller, Linh, Falzon, Jaramillo (bib0010) 2018; 15 Kaplan, Fraser, Comstock (bib0090) 1972; 105 Zumla, Marais, McHugh, Maeurer, Zumla, Kapata (bib0180) 2020; 24 Parwati, Farid, Nasution, Sulisty, Basri, Lolong (bib0120) 2020; 24 Reid, Arinaminpathy, Bloom, Bloom, Boehme, Chaisson (bib0125) 2019 Romanowski, Baumann, Basham, Ahmad Khan, Fox, Johnston (bib0130) 2019; 19 Cox, Brigden, Crespo, Lessem, Lynch, Rich (bib0050) 2018; 22 Volmink, Garner (bib0165) 2007 Marks, Nguyen, Nguyen, Nguyen, Nguyen, Tran (bib0100) 2019; 381 Sumner, Scriba, Penn-Nicholson, Hatherill, White (bib0145) 2019; 9 Ngwatu, Placide, Olivia, Benjamin, Linh, Ernesto (bib0105) 2018; 51 Grace, Mittal, Jain, Tripathy, Satyanarayana, Tharyan (bib0080) 2019; 12 Chakaya, Kirenga, Getahun (bib0040) 2016; 3 Forni, Mantovani (bib0065) 2021 Garcıa-Basteiro, Brew, Williams, Borgdorff, Cobelens (bib0070) 2018; 47 WHO (bib0170) 2020 Allwood, Van Der Zalm, Amaral, Byrne, Datta, Egere (bib0020) 2020; 24 Diacon, Pym, Grobusch, de Los Rios, Gotuzzo, Vasilyeva (bib0055) 2014; 371 Corbett (10.1016/j.ijid.2021.02.107_bib0045) 2010; 376 Trebucq (10.1016/j.ijid.2021.02.107_bib0160) 2018; 22 WHO (10.1016/j.ijid.2021.02.107_bib0170) 2020 Diacon (10.1016/j.ijid.2021.02.107_bib0055) 2014; 371 Zumla (10.1016/j.ijid.2021.02.107_bib0180) 2020; 24 Parwati (10.1016/j.ijid.2021.02.107_bib0120) 2020; 24 Bulabula (10.1016/j.ijid.2021.02.107_bib0030) 2019; 69 Cegielski (10.1016/j.ijid.2021.02.107_bib0035) 2014; 59 Trébucq (10.1016/j.ijid.2021.02.107_bib0155) 2016; 20 Cox (10.1016/j.ijid.2021.02.107_bib0050) 2018; 22 Swindells (10.1016/j.ijid.2021.02.107_bib0150) 2019; 380 Gler (10.1016/j.ijid.2021.02.107_bib0075) 2012; 366 Ngwatu (10.1016/j.ijid.2021.02.107_bib0105) 2018; 51 WHO (10.1016/j.ijid.2021.02.107_bib0175) 2019 Nunn (10.1016/j.ijid.2021.02.107_bib0115) 2019; 380 Grace (10.1016/j.ijid.2021.02.107_bib0080) 2019; 12 Romanowski (10.1016/j.ijid.2021.02.107_bib0130) 2019; 19 Reid (10.1016/j.ijid.2021.02.107_bib0125) 2019 Sumner (10.1016/j.ijid.2021.02.107_bib0145) 2019; 9 Garcıa-Basteiro (10.1016/j.ijid.2021.02.107_bib0070) 2018; 47 Forni (10.1016/j.ijid.2021.02.107_bib0065) 2021 Bisimwa (10.1016/j.ijid.2021.02.107_bib0025) 2020; 26 Allwood (10.1016/j.ijid.2021.02.107_bib0015) 2019; 9 Marks (10.1016/j.ijid.2021.02.107_bib0100) 2019; 381 Subbaraman (10.1016/j.ijid.2021.02.107_bib0140) 2019; 16 African Union (10.1016/j.ijid.2021.02.107_bib0005) 2007 Chakaya (10.1016/j.ijid.2021.02.107_bib0040) 2016; 3 Lee (10.1016/j.ijid.2021.02.107_bib0095) 2020; 8 Sterling (10.1016/j.ijid.2021.02.107_bib0135) 2011; 365 Allwood (10.1016/j.ijid.2021.02.107_bib0020) 2020; 24 Kaplan (10.1016/j.ijid.2021.02.107_bib0090) 1972; 105 Noubiap (10.1016/j.ijid.2021.02.107_bib0110) 2019; 7 Dooley (10.1016/j.ijid.2021.02.107_bib0060) 2009; 9 Volmink (10.1016/j.ijid.2021.02.107_bib0165) 2007 Alipanah (10.1016/j.ijid.2021.02.107_bib0010) 2018; 15 Houben (10.1016/j.ijid.2021.02.107_bib0085) 2016; 13 |
| References_xml | – volume: 380 start-page: 1001 year: 2019 end-page: 1011 ident: bib0150 article-title: One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis publication-title: N Engl J Med – volume: 24 start-page: 820 year: 2020 end-page: 828 ident: bib0020 article-title: Post-tuberculosis lung health: Perspectives from the First International Symposium publication-title: Int J Tuberc Lung Dis – volume: 105 start-page: 920 year: 1972 end-page: 926 ident: bib0090 article-title: Tuberculosis in Alaska, 1970. The continued decline of the tuberculosis epidemic publication-title: Am Rev Respir Dis – volume: 47 start-page: 1549 year: 2018 end-page: 1560 ident: bib0070 article-title: What is the true tuberculosis mortality burden? Differences in estimates by the World Health Organization and the Global Burden of Disease study publication-title: Int J Epidemiol – volume: 8 start-page: E1427 year: 2020 end-page: E1434 ident: bib0095 article-title: Adverse health effects associated with household air pollution: a systematic review, meta-analysis, and burden estimation study publication-title: Lancet Glob Heal – volume: 26 start-page: ciaa873 year: 2020 ident: bib0025 article-title: Xpert Mycobacterium tuberculosis/Rifampicin–Detected Rifampicin Resistance is a Suboptimal Surrogate for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications publication-title: Clin Infect Dis – volume: 9 start-page: 737 year: 2009 end-page: 746 ident: bib0060 article-title: Tuberculosis and diabetes mellitus: convergence of two epidemics publication-title: Lancet Infect Dis – volume: 15 start-page: e1002595 year: 2018 ident: bib0010 article-title: Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies publication-title: PLoS Med – year: 2007 ident: bib0165 article-title: Directly observed therapy for treating tuberculosis publication-title: Cochrane Database Syst Rev – year: 2019 ident: bib0175 article-title: Global Task Force on TB Impact Measurement. World Heal Organ – volume: 24 start-page: 757 year: 2020 end-page: 760 ident: bib0180 article-title: COVID-19 and tuberculosis-threats and opportunities publication-title: Int J Tuberc Lung Dis – volume: 9 start-page: 1170 year: 2019 end-page: 1171 ident: bib0015 article-title: The long shadow post-tuberculosis publication-title: Lancet Infect Dis – volume: 19 start-page: 1129 year: 2019 end-page: 1137 ident: bib0130 article-title: Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis publication-title: Lancet Infect Dis – volume: 3 start-page: 10 year: 2016 end-page: 12 ident: bib0040 article-title: Long term complications after completion of pulmonary tuberculosis treatment: A quest for a public health approach publication-title: J Clin Tuberc Other Mycobact Dis – volume: 22 start-page: 407 year: 2018 end-page: 412 ident: bib0050 article-title: Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis publication-title: Int J Tuberc Lung Dis – volume: 366 start-page: 2151 year: 2012 end-page: 2160 ident: bib0075 article-title: Delamanid for multidrug-resistant pulmonary tuberculosis publication-title: N Engl J Med – volume: 51 year: 2018 ident: bib0105 article-title: The impact of digital health technologies on tuberculosis treatment: A systematic review publication-title: Eur Respir J – volume: 371 start-page: 723 year: 2014 end-page: 732 ident: bib0055 article-title: Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline publication-title: N Engl J Med – volume: 381 start-page: 1347 year: 2019 end-page: 1357 ident: bib0100 article-title: Community-wide screening for Tuberculosis in a high-prevalence setting publication-title: N Engl J Med – volume: 12 year: 2019 ident: bib0080 article-title: Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis publication-title: Cochrane Database Syst Rev – volume: 24 start-page: 250 year: 2020 end-page: 257 ident: bib0120 article-title: Estimation of subnational tuberculosis burden: Generation and application of a new tool in Indonesia publication-title: Int J Tuberc Lung Dis – year: 2019 ident: bib0125 article-title: Building a tuberculosis-free world: The Lancet Commission on tuberculosis publication-title: Lancet – year: 2021 ident: bib0065 article-title: COVID-19 vaccines: where we stand and challenges ahead publication-title: Cell Death Differ – volume: 16 start-page: e1002754 year: 2019 ident: bib0140 article-title: Constructing care cascades for active tuberculosis: A strategy for program monitoring and identifying gaps in quality of care publication-title: PLoS Med – volume: 13 start-page: e1002152 year: 2016 ident: bib0085 article-title: The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling publication-title: PLoS Med – volume: 365 start-page: 2155 year: 2011 end-page: 2166 ident: bib0135 article-title: Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection publication-title: N Engl J Med – volume: 22 start-page: 17 year: 2018 end-page: 25 ident: bib0160 article-title: Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries publication-title: Int J Tuberc Lung Dis – year: 2020 ident: bib0170 article-title: Global Tuberculosis Report 2020 – volume: 376 start-page: 1244 year: 2010 end-page: 1253 ident: bib0045 article-title: Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): A cluster-randomised trial publication-title: Lancet – volume: 59 start-page: 1049 year: 2014 end-page: 1063 ident: bib0035 article-title: Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis publication-title: Clin Infect Dis – start-page: 164 year: 2007 ident: bib0005 article-title: Assembly of the African Union 8th Ordinary Session – volume: 380 start-page: 1201 year: 2019 end-page: 1213 ident: bib0115 article-title: A trial of a shorter regimen for Rifampin-resistant tuberculosis publication-title: N Engl J Med – volume: 7 start-page: e448 year: 2019 end-page: e460 ident: bib0110 article-title: Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2·3 million patients with tuberculosis publication-title: Lancet Glob Heal – volume: 20 start-page: 1288 year: 2016 end-page: 1292 ident: bib0155 article-title: Numbers of tuberculosis cases: Dreams and reality publication-title: Int J Tuberc Lung Dis – volume: 69 start-page: 1278 year: 2019 end-page: 1287 ident: bib0030 article-title: Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF–identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012–2017: A Retrospective Province-Wide Cohort Study publication-title: Clin Infect Dis – volume: 9 start-page: 11126 year: 2019 ident: bib0145 article-title: Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy publication-title: Sci Rep – volume: 9 start-page: 11126 year: 2019 ident: 10.1016/j.ijid.2021.02.107_bib0145 article-title: Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy publication-title: Sci Rep doi: 10.1038/s41598-019-47645-z – volume: 26 start-page: ciaa873 year: 2020 ident: 10.1016/j.ijid.2021.02.107_bib0025 article-title: Xpert Mycobacterium tuberculosis/Rifampicin–Detected Rifampicin Resistance is a Suboptimal Surrogate for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications publication-title: Clin Infect Dis – volume: 69 start-page: 1278 issue: 8 year: 2019 ident: 10.1016/j.ijid.2021.02.107_bib0030 article-title: Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF–identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012–2017: A Retrospective Province-Wide Cohort Study publication-title: Clin Infect Dis doi: 10.1093/cid/ciy1105 – volume: 20 start-page: 1288 issue: 10 year: 2016 ident: 10.1016/j.ijid.2021.02.107_bib0155 article-title: Numbers of tuberculosis cases: Dreams and reality publication-title: Int J Tuberc Lung Dis doi: 10.5588/ijtld.15.0873 – volume: 9 start-page: 1170 issue: 11 year: 2019 ident: 10.1016/j.ijid.2021.02.107_bib0015 article-title: The long shadow post-tuberculosis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(19)30564-X – year: 2021 ident: 10.1016/j.ijid.2021.02.107_bib0065 article-title: COVID-19 vaccines: where we stand and challenges ahead publication-title: Cell Death Differ doi: 10.1038/s41418-020-00720-9 – year: 2019 ident: 10.1016/j.ijid.2021.02.107_bib0175 – volume: 381 start-page: 1347 year: 2019 ident: 10.1016/j.ijid.2021.02.107_bib0100 article-title: Community-wide screening for Tuberculosis in a high-prevalence setting publication-title: N Engl J Med doi: 10.1056/NEJMoa1902129 – volume: 8 start-page: E1427 issue: 11 year: 2020 ident: 10.1016/j.ijid.2021.02.107_bib0095 article-title: Adverse health effects associated with household air pollution: a systematic review, meta-analysis, and burden estimation study publication-title: Lancet Glob Heal doi: 10.1016/S2214-109X(20)30343-0 – volume: 12 year: 2019 ident: 10.1016/j.ijid.2021.02.107_bib0080 article-title: Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis publication-title: Cochrane Database Syst Rev – volume: 22 start-page: 17 issue: 1 year: 2018 ident: 10.1016/j.ijid.2021.02.107_bib0160 article-title: Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries publication-title: Int J Tuberc Lung Dis doi: 10.5588/ijtld.17.0498 – volume: 9 start-page: 737 issue: 12 year: 2009 ident: 10.1016/j.ijid.2021.02.107_bib0060 article-title: Tuberculosis and diabetes mellitus: convergence of two epidemics publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(09)70282-8 – volume: 19 start-page: 1129 issue: 10 year: 2019 ident: 10.1016/j.ijid.2021.02.107_bib0130 article-title: Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(19)30309-3 – volume: 371 start-page: 723 year: 2014 ident: 10.1016/j.ijid.2021.02.107_bib0055 article-title: Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline publication-title: N Engl J Med doi: 10.1056/NEJMoa1313865 – volume: 22 start-page: 407 issue: 4 year: 2018 ident: 10.1016/j.ijid.2021.02.107_bib0050 article-title: Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis publication-title: Int J Tuberc Lung Dis doi: 10.5588/ijtld.17.0706 – start-page: 164 year: 2007 ident: 10.1016/j.ijid.2021.02.107_bib0005 – volume: 51 year: 2018 ident: 10.1016/j.ijid.2021.02.107_bib0105 article-title: The impact of digital health technologies on tuberculosis treatment: A systematic review publication-title: Eur Respir J doi: 10.1183/13993003.01596-2017 – year: 2019 ident: 10.1016/j.ijid.2021.02.107_bib0125 article-title: Building a tuberculosis-free world: The Lancet Commission on tuberculosis publication-title: Lancet doi: 10.1016/S0140-6736(19)30024-8 – year: 2020 ident: 10.1016/j.ijid.2021.02.107_bib0170 – volume: 15 start-page: e1002595 issue: 7 year: 2018 ident: 10.1016/j.ijid.2021.02.107_bib0010 article-title: Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies publication-title: PLoS Med doi: 10.1371/journal.pmed.1002595 – volume: 7 start-page: e448 issue: 4 year: 2019 ident: 10.1016/j.ijid.2021.02.107_bib0110 article-title: Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2·3 million patients with tuberculosis publication-title: Lancet Glob Heal doi: 10.1016/S2214-109X(18)30487-X – volume: 47 start-page: 1549 issue: 5 year: 2018 ident: 10.1016/j.ijid.2021.02.107_bib0070 article-title: What is the true tuberculosis mortality burden? Differences in estimates by the World Health Organization and the Global Burden of Disease study publication-title: Int J Epidemiol doi: 10.1093/ije/dyy144 – volume: 13 start-page: e1002152 issue: 10 year: 2016 ident: 10.1016/j.ijid.2021.02.107_bib0085 article-title: The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling publication-title: PLoS Med doi: 10.1371/journal.pmed.1002152 – volume: 24 start-page: 757 issue: 8 year: 2020 ident: 10.1016/j.ijid.2021.02.107_bib0180 article-title: COVID-19 and tuberculosis-threats and opportunities publication-title: Int J Tuberc Lung Dis doi: 10.5588/ijtld.20.0387 – volume: 380 start-page: 1201 year: 2019 ident: 10.1016/j.ijid.2021.02.107_bib0115 article-title: A trial of a shorter regimen for Rifampin-resistant tuberculosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1811867 – volume: 366 start-page: 2151 year: 2012 ident: 10.1016/j.ijid.2021.02.107_bib0075 article-title: Delamanid for multidrug-resistant pulmonary tuberculosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1112433 – volume: 24 start-page: 820 issue: 8 year: 2020 ident: 10.1016/j.ijid.2021.02.107_bib0020 article-title: Post-tuberculosis lung health: Perspectives from the First International Symposium publication-title: Int J Tuberc Lung Dis doi: 10.5588/ijtld.20.0067 – volume: 24 start-page: 250 issue: 2 year: 2020 ident: 10.1016/j.ijid.2021.02.107_bib0120 article-title: Estimation of subnational tuberculosis burden: Generation and application of a new tool in Indonesia publication-title: Int J Tuberc Lung Dis doi: 10.5588/ijtld.19.0139 – volume: 365 start-page: 2155 year: 2011 ident: 10.1016/j.ijid.2021.02.107_bib0135 article-title: Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection publication-title: N Engl J Med doi: 10.1056/NEJMoa1104875 – volume: 376 start-page: 1244 issue: 9748 year: 2010 ident: 10.1016/j.ijid.2021.02.107_bib0045 article-title: Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): A cluster-randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(10)61425-0 – volume: 59 start-page: 1049 issue: 8 year: 2014 ident: 10.1016/j.ijid.2021.02.107_bib0035 article-title: Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis publication-title: Clin Infect Dis doi: 10.1093/cid/ciu572 – volume: 3 start-page: 10 year: 2016 ident: 10.1016/j.ijid.2021.02.107_bib0040 article-title: Long term complications after completion of pulmonary tuberculosis treatment: A quest for a public health approach publication-title: J Clin Tuberc Other Mycobact Dis doi: 10.1016/j.jctube.2016.03.001 – volume: 380 start-page: 1001 year: 2019 ident: 10.1016/j.ijid.2021.02.107_bib0150 article-title: One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1806808 – year: 2007 ident: 10.1016/j.ijid.2021.02.107_bib0165 article-title: Directly observed therapy for treating tuberculosis publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD003343.pub3 – volume: 105 start-page: 920 issue: 6 year: 1972 ident: 10.1016/j.ijid.2021.02.107_bib0090 article-title: Tuberculosis in Alaska, 1970. The continued decline of the tuberculosis epidemic publication-title: Am Rev Respir Dis – volume: 16 start-page: e1002754 issue: 2 year: 2019 ident: 10.1016/j.ijid.2021.02.107_bib0140 article-title: Constructing care cascades for active tuberculosis: A strategy for program monitoring and identifying gaps in quality of care publication-title: PLoS Med doi: 10.1371/journal.pmed.1002754 |
| SSID | ssj0004668 |
| Score | 2.7188244 |
| Snippet | •In 2020, COVID-19 dislodged TB as the top infectious disease cause of mortality globally.•Globally, an estimated 10.0 million people developed active TB... The October 2020 Global TB report reviews TB control strategies and United Nations (UN) targets set in the political declaration at the September 2018 UN... |
| SourceID | doaj swepub pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | S7 |
| SubjectTerms | Adult Child COVID-19 Global TB Report 2020 Humans Nigeria Pandemics Prevention RNA, Viral SARS-CoV-2 Treatment Tuberculosis Tuberculosis, Miliary |
| Title | Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1201971221001934 https://dx.doi.org/10.1016/j.ijid.2021.02.107 https://www.ncbi.nlm.nih.gov/pubmed/33716195 https://www.proquest.com/docview/2501482845 https://pubmed.ncbi.nlm.nih.gov/PMC8433257 http://kipublications.ki.se/Default.aspx?queryparsed=id:148554665 https://doaj.org/article/af3537cdd0084b9db6585c467efbfe04 |
| Volume | 113 |
| WOSCitedRecordID | wos000735777000002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1878-3511 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004668 issn: 1201-9712 databaseCode: DOA dateStart: 19960101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagQgipqqC8tkBlJMQFIuLXJjlSRMWFikOR9mb5MRZpV9lqs9tz_0P_Ib-EcZxEjSq1F24bx7NZ2-PMN-uZbwj5YCtmgyhNNvfgMjlHd8fOvc9yVzGjGNo8brpiE8XJSblYVL9ulPqKMWGJHjhN3BcThBKF8z4yv9vKWxRXDrc3BBsgMYHmRTU4U2NGZEqCQ_OWVQXjfbpMiuyqz-rIEco7tk4WC8neMEkdc__EMt1GnrcDKCc0o51pOn5K9npMSb-msTwjD6DZJ49_9qfm-2Q3_TdHU8rRc1Inon96urWwdtvlqq1bmpA4xR-c079X13gdll2YVtPSVUMRJ9JB7IjaLvnhMx3D1KlpPL3o6aCwO4QQjyJekN_H30-__cj6kguZQxy1yQIYVebKWoRNDCAYw0zOnPSeM2EBQAgfvK8Ul96Zgvm5dRwbJfe5d0KKl2SnWTXwmlBpEd1xy4VXVno0gQoYE4DuYDAWSpgRNsy6dj0feSyLsdRD4NmZjiul40rpnGNbMSOfRpmLxMZxZ--juJhjz8ik3TWgfulev_R9-jUjYlAFPSSr4usVv6i-89FqlOqhTIIo98q9H7RN4z6PhzemgdW21TweAKN7LNWMvEraNw5MCPR6WYV3ioleTkY-vdPUfzou8TLy1yl87sekwRORvukcP4GWCE1LdfA_5vQNeRLHnKKC3pKdzXoL78gjd7mp2_UheVgsysNuP_8DOdpQ0A |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Global+Tuberculosis+Report+2020+-+Reflections+on+the+Global+TB+burden%2C+treatment+and+prevention+efforts&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Chakaya%2C+Jeremiah&rft.au=Khan%2C+Mishal&rft.au=Ntoumi%2C+Francine&rft.au=Aklillu%2C+Eleni&rft.date=2021-12-01&rft.eissn=1878-3511&rft.volume=113+Suppl+1&rft.spage=S7&rft_id=info:doi/10.1016%2Fj.ijid.2021.02.107&rft_id=info%3Apmid%2F33716195&rft.externalDocID=33716195 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon |